Aethlon Medical Inc.
| NASDAQ: AEMD | Healthcare / Medical Devices & Instruments / USA |
| 0.2001 | -0.0199 | -9.05% | Vol 420.18K | 1Y Perf -67.16% |
| Oct 4th, 2023 15:37 DELAYED |
| BID | 0.2001 | ASK | 0.2044 | ||
| Open | 0.2070 | Previous Close | 0.2200 | ||
| Pre-Market | 0.21 | After-Market | - | ||
| -0.01 -4.64% | - - |
| Target Price | 7.50 | Analyst Rating | Hold 3.00 | |
| Potential % | 3.65K | Finscreener Ranking | ★★+ 47.44 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 53.97 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 49.62 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -1.52 | Earnings Rating | Strong Buy | |
| Market Cap | 4.97M | Earnings Date | 13th Nov 2023 | |
| Alpha | 0.01 | Standard Deviation | 0.59 | |
| Beta | 1.35 |
Today's Price Range 0.20000.2290 | 52W Range 0.21010.8700 | 5 Year PE Ratio Range -1.70-1.50 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.00% | ||
| 1 Month | -21.43% | ||
| 3 Months | -37.11% | ||
| 6 Months | -43.01% | ||
| 1 Year | -67.16% | ||
| 3 Years | -83.70% | ||
| 5 Years | -98.74% | ||
| 10 Years | -99.81% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -85.79 | |||
ROE last 12 Months | -66.15 | |||
ROA (5Y Avg) | -24.32 | |||
ROA last 12 Months | -60.21 | |||
ROC (5Y Avg) | -75.19 | |||
ROC last 12 Months | -57.19 | |||
Return on invested Capital Q | -20.60 | |||
Return on invested Capital Y | -19.46 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.60 | ||||
| 0.55 | ||||
| 775.37 | ||||
| - | ||||
| -1.10 | ||||
| -0.50 | ||||
| 0.55 | ||||
| 0.87 | ||||
| -7 267 460.00 | ||||
| Forward PE | -0.41 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.40 | ||||
| 9.80 | ||||
| 0.05 | ||||
| 0.07 | ||||
| -83 366.10 | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -42 624.60 | ||||
| -42 207.10 | ||||
| -4 145.90 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.12K | ||||
| 0.00 | ||||
| -59.98 | ||||
| 10.98 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | -0.12 | -0.13 | -8.33 |
| Q04 2023 | -0.16 | -0.11 | 31.25 |
| Q03 2023 | -0.04 | -0.12 | -200.00 |
| Q02 2023 | -0.23 | -0.18 | 21.74 |
| Q01 2023 | -0.24 | -0.19 | 20.83 |
| Q04 2022 | -0.12 | -0.25 | -108.33 |
| Q03 2022 | -0.13 | -0.16 | -23.08 |
| Q02 2022 | -0.15 | -0.13 | 13.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.13 | 7.14 | Positive |
| 12/2023 QR | -0.13 | 7.14 | Positive |
| 3/2024 FY | -0.52 | 5.45 | Positive |
| 3/2024 FY | -0.55 | 0.00 | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.13 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 420.18K |
| Shares Outstanding | 24.84K |
| Shares Float | 24.04M |
| Trades Count | 24.31K |
| Dollar Volume | 86.29K |
| Avg. Volume | 134.93K |
| Avg. Weekly Volume | 64.28K |
| Avg. Monthly Volume | 90.06K |
| Avg. Quarterly Volume | 250.45K |
Aethlon Medical Inc. (NASDAQ: AEMD) stock closed at 0.22 per share at the end of the most recent trading day (a -3.93% change compared to the prior day closing price) with a volume of 36.17K shares and market capitalization of 4.97M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8 people. Aethlon Medical Inc. CEO is Charles J. Fisher.
The one-year performance of Aethlon Medical Inc. stock is -67.16%, while year-to-date (YTD) performance is -20.12%. AEMD stock has a five-year performance of -98.74%. Its 52-week range is between 0.2101 and 0.87, which gives AEMD stock a 52-week price range ratio of -1.52%
Aethlon Medical Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.55, a price-to-sale (PS) ratio of 775.37, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -60.21%, a ROC of -57.19% and a ROE of -66.15%. The company’s profit margin is -%, its EBITDA margin is -42 207.10%, and its revenue ttm is $13.12 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aethlon Medical Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Aethlon Medical Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Aethlon Medical Inc. is Hold (3), with a target price of $7.5, which is +3 648.13% compared to the current price. The earnings rating for Aethlon Medical Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aethlon Medical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aethlon Medical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.16, ATR14 : 0.02, CCI20 : -85.64, Chaikin Money Flow : -0.42, MACD : -0.02, Money Flow Index : 16.88, ROC : -18.52, RSI : 32.96, STOCH (14,3) : 13.43, STOCH RSI : 0.75, UO : 32.08, Williams %R : -86.57), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aethlon Medical Inc. in the last 12-months were:
Aethlon Medical Inc.
Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment.
CEO: Charles J. Fisher
Telephone: +1 858 459-7800
Address: 9635 Granite Ridge Drive, San Diego 92123, CA, US
Number of employees: 8
